Antiviral Agents against Omicron Subvariant BA.4.6 In Vitro
To the Editor: Studies have shown that the neutralization activity of antibodies such as S309 (the precursor of sotrovimab) or sotrovimab, which bind outside the receptor-binding motif (RBM), depends on the expression level of the SARS-CoV-2 receptor (angiotensin-converting enzyme 2 [ACE2]), whereas...
Saved in:
| Published in | The New England journal of medicine Vol. 388; no. 5; p. e12 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Massachusetts Medical Society
02.02.2023
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | To the Editor:
Studies have shown that the neutralization activity of antibodies such as S309 (the precursor of sotrovimab) or sotrovimab, which bind outside the receptor-binding motif (RBM), depends on the expression level of the SARS-CoV-2 receptor (angiotensin-converting enzyme 2 [ACE2]), whereas the activity of RBM-targeting monoclonal antibodies is not considerably affected by ACE2 receptor expression.
1,2
Three recent letters in the
Journal
from a group at the University of Tokyo (Aug. 4 and Dec. 1, 2022, and Jan. 5, 2023, issues)
3-5
reported substantial loss of in vitro neutralization activity with S309 against recent B.1.1.529 (omicron) variants. This group cites the . . . |
|---|---|
| AbstractList | To the Editor:
Studies have shown that the neutralization activity of antibodies such as S309 (the precursor of sotrovimab) or sotrovimab, which bind outside the receptor-binding motif (RBM), depends on the expression level of the SARS-CoV-2 receptor (angiotensin-converting enzyme 2 [ACE2]), whereas the activity of RBM-targeting monoclonal antibodies is not considerably affected by ACE2 receptor expression.
1,2
Three recent letters in the
Journal
from a group at the University of Tokyo (Aug. 4 and Dec. 1, 2022, and Jan. 5, 2023, issues)
3-5
reported substantial loss of in vitro neutralization activity with S309 against recent B.1.1.529 (omicron) variants. This group cites the . . . To the Editor: Studies have shown that the neutralization activity of antibodies such as S309 (the precursor of sotrovimab) or sotrovimab, which bind outside the receptor-binding motif (RBM), depends on the expression level of the SARS-CoV-2 receptor (angiotensin-converting enzyme 2 [ACE2]), whereas the activity of RBM-targeting monoclonal antibodies is not considerably affected by ACE2 receptor expression.1,2 Three recent letters in the Journal from a group at the University of Tokyo (Aug. 4 and Dec. 1, 2022, and Jan. 5, 2023, issues)3-5 reported substantial loss of in vitro neutralization activity with S309 against recent B.1.1.529 (omicron) variants. This group cites the . . . |
| Author | Kerr, William Schnell, Gretja Imai, Masaki Uraki, Ryuta Kawaoka, Yoshihiro Walker, Jill |
| Author_xml | – sequence: 1 givenname: Jill surname: Walker fullname: Walker, Jill organization: GSK, San Francisco, CA – sequence: 2 givenname: Gretja surname: Schnell fullname: Schnell, Gretja organization: Vir Biotechnology, San Francisco, CA – sequence: 3 givenname: William surname: Kerr fullname: Kerr, William email: william.x.kerr@gsk.com organization: GSK, London, United Kingdom – sequence: 4 givenname: Ryuta surname: Uraki fullname: Uraki, Ryuta email: yoshihiro.kawaoka@wisc.edu organization: University of Tokyo, Tokyo, Japan – sequence: 5 givenname: Masaki surname: Imai fullname: Imai, Masaki email: yoshihiro.kawaoka@wisc.edu organization: University of Tokyo, Tokyo, Japan – sequence: 6 givenname: Yoshihiro surname: Kawaoka fullname: Kawaoka, Yoshihiro email: yoshihiro.kawaoka@wisc.edu organization: University of Tokyo, Tokyo, Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36724340$$D View this record in MEDLINE/PubMed |
| BookMark | eNp10DlPwzAUwHELgWg5NmYUCQYGUvx8JRFTqTiKgA4ca-S4buUqccB2kPj2GFoQQuDlLb_3ZP230LptrUZoD_AAMBcnd-fXt4oQEAJgDfWBU5oyhsU66mNM8pRlBe2hLe8XOD5gxSbqUZERRhnuo9OhDebVOFknw7m2wSdyLo31IZk0RrnWJvdd9SqdkTYkZ8MBG4hkbJMnE1y7gzZmsvZ6dzW30ePF-cPoKr2ZXI5Hw5tUMU5CqhTwYsqBzAqaqQIKpjJaTSHPgEnJqYSp0BozXbEZzTUoyhRnFdU8J7kWim6jo-XdZ9e-dNqHsjFe6bqWVredL0mWxaMADEd68Isu2s7Z-LtPJXIeG0S1v1Jd1ehp-exMI91b-ZUlguMliAW8d3r2TQCXH9XLn9UjJ7-4MkEG09rgpKn_WzpcLjWNL61eNH-zd44Ei3Q |
| CitedBy_id | crossref_primary_10_1016_S1473_3099_23_00132_9 crossref_primary_10_1007_s15010_025_02505_z crossref_primary_10_1007_s40261_024_01344_4 |
| Cites_doi | 10.1056/NEJMc2207519 10.1016/j.redox.2020.101615 10.1038/s41467-022-31615-7 10.1038/s41586-021-03925-1 10.1056/NEJMc2211845 10.1056/NEJMc2214302 10.3390/v14092061 |
| ContentType | Journal Article |
| Copyright | Copyright © 2023 Massachusetts Medical Society. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2023 Massachusetts Medical Society. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7RV 7X7 7XB 8AO 8C1 8FE 8FH 8FI ABUWG AFKRA AN0 AZQEC BBNVY BEC BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH HCIFZ K0Y LK8 M0R M0T M1P M2M M2O M2P M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 |
| DOI | 10.1056/NEJMc2216611 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection Public Health Database (ProQuest) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Central Essentials Biological Science Collection eLibrary ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library SciTech Premium Collection New England Journal of Medicine Biological Sciences Consumer Health Database Healthcare Administration Database Medical Database Psychology Database Research Library Science Database Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials elibrary ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing New England Journal of Medicine ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Research Library ProQuest Central (New) ProQuest Public Health ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest Family Health ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Psychology |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1533-4406 |
| ExternalDocumentID | 36724340 10_1056_NEJMc2216611 NJ202302023880521 |
| Genre | Correspondence Letter Comment Commentary |
| GeographicLocations | United States--US San Francisco California |
| GeographicLocations_xml | – name: San Francisco California – name: United States--US |
| GroupedDBID | --- -DZ -ET -~X .-4 .55 .CO .GJ 0R~ 0WA 123 1VV 2KS 2WC 34G 36B 39C 4.4 5RE 7FN 7RV 7X7 85S 8C1 8W4 9M8 AACLI AAEJM AAIKC AAMNW AAQQT AARDX AAUTI AAWTL ABACO ABEHJ ABFLS ABIVO ABOCM ABPPZ ABPTK ABQIJ ABWJO ACGFS ACGOD ACKOT ACNCT ACPRK ACPVT ACRZS ADBBV AENEX AETEA AFFNX AFHKK AFOSN AFUVZ AGFXO AGNAY AHMBA AJJEV ALMA_UNASSIGNED_HOLDINGS BBNVY BENPR C45 CJ0 CS3 DCD DU5 EBS EX3 F5P FD8 FM. HCIFZ HF~ HZ~ I4R K-O KOO L7B M0R M0T M1P M2M M2O M2P M7P MQT MVM N4W NEJ O9- OK1 OMK OVD P-O P2P RHI RWL RXW S10 SJN TAE TAF TEORI TN5 TWZ UCV UKR UMD VQA W2G WH7 WOQ WOW X7M XJT XYN XZL YCJ YFH YR2 YRY YYP YZZ ZA5 ZCA ZR0 ZVN ~KM 29N 53G 8AO 8FE 8FH 8FI AAYXX ABBLC ABDQB ABJNI ABUWG ACPFK ADUKH AERZD AFKRA AGHSJ ALIPV AN0 AQUVI AZQEC BCU BHPHI BKEYQ BKNYI BNQBC BPHCQ BVXVI BYPQX CCPQU CITATION DWQXO FYUFA GNUQQ GUQSH HMCUK LK8 NAPCQ PCD PHGZM PHGZT PQQKQ PROAC PSQYO PSYQQ SJFOW TUQ UKHRP YR5 ABCQX CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB 7XB BEC K0Y MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 |
| ID | FETCH-LOGICAL-c452t-cc159d512f937c9194c73bd18714aa53a1d6ee04eb4f38e1c34c54b3e5828e6c3 |
| IEDL.DBID | 7X7 |
| ISSN | 0028-4793 1533-4406 |
| IngestDate | Fri Jul 11 15:40:52 EDT 2025 Sat Aug 23 12:45:20 EDT 2025 Mon Jul 21 05:54:58 EDT 2025 Thu Jul 03 08:43:47 EDT 2025 Thu Apr 24 23:00:27 EDT 2025 Mon Feb 06 02:07:02 EST 2023 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c452t-cc159d512f937c9194c73bd18714aa53a1d6ee04eb4f38e1c34c54b3e5828e6c3 |
| Notes | SourceType-Scholarly Journals-1 ObjectType-Correspondence-1 content type line 14 ObjectType-Commentary-2 content type line 23 |
| OpenAccessLink | https://www.nejm.org/doi/pdf/10.1056/NEJMc2216611?articleTools=true |
| PMID | 36724340 |
| PQID | 2771685000 |
| PQPubID | 40644 |
| ParticipantIDs | proquest_miscellaneous_2771941140 proquest_journals_2771685000 pubmed_primary_36724340 crossref_primary_10_1056_NEJMc2216611 crossref_citationtrail_10_1056_NEJMc2216611 mms_nejm_10_1056_NEJMc2216611 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-02-02 |
| PublicationDateYYYYMMDD | 2023-02-02 |
| PublicationDate_xml | – month: 02 year: 2023 text: 2023-02-02 day: 02 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Boston |
| PublicationTitle | The New England journal of medicine |
| PublicationTitleAlternate | N Engl J Med |
| PublicationYear | 2023 |
| Publisher | Massachusetts Medical Society |
| Publisher_xml | – name: Massachusetts Medical Society |
| References | e_1_2_3_2_4_2 e_1_2_3_2_3_2 e_1_2_3_2_6_2 e_1_2_3_2_5_2 e_1_3_3_2_3_2 e_1_3_3_2_2_2 e_1_2_3_2_2_2 36383452 - N Engl J Med. 2022 Dec 1;387(22):2094-2097 36724341 - N Engl J Med. 2023 Feb 2;388(5):e12 |
| References_xml | – ident: e_1_2_3_2_4_2 doi: 10.1056/NEJMc2207519 – ident: e_1_3_3_2_2_2 doi: 10.1016/j.redox.2020.101615 – ident: e_1_3_3_2_3_2 doi: 10.1038/s41467-022-31615-7 – ident: e_1_2_3_2_2_2 doi: 10.1038/s41586-021-03925-1 – ident: e_1_2_3_2_5_2 doi: 10.1056/NEJMc2211845 – ident: e_1_2_3_2_6_2 doi: 10.1056/NEJMc2214302 – ident: e_1_2_3_2_3_2 doi: 10.3390/v14092061 – reference: 36383452 - N Engl J Med. 2022 Dec 1;387(22):2094-2097 – reference: 36724341 - N Engl J Med. 2023 Feb 2;388(5):e12 |
| SSID | ssj0000149 |
| Score | 2.4460647 |
| Snippet | To the Editor:
Studies have shown that the neutralization activity of antibodies such as S309 (the precursor of sotrovimab) or sotrovimab, which bind outside... To the Editor: Studies have shown that the neutralization activity of antibodies such as S309 (the precursor of sotrovimab) or sotrovimab, which bind outside... |
| SourceID | proquest pubmed crossref mms |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e12 |
| SubjectTerms | ACE2 Angiotensin Angiotensin-converting enzyme 2 Antiviral agents Antiviral Agents - therapeutic use Conflicts of interest Humans Monoclonal antibodies Peptidyl-dipeptidase A Severe acute respiratory syndrome coronavirus 2 |
| Title | Antiviral Agents against Omicron Subvariant BA.4.6 In Vitro |
| URI | https://nejm.org/doi/full/10.1056/NEJMc2216611 https://www.ncbi.nlm.nih.gov/pubmed/36724340 https://www.proquest.com/docview/2771685000 https://www.proquest.com/docview/2771941140 |
| Volume | 388 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT8IwEG8UEuOL8VsUyEz0yQy2tesgPhggEDQBjRHD29J2ndHIUDb9-70bBfEBX_ayy7Lctb3fffR-hFyAiRtcChfCEidP3XBbBLAfY4_6ToSkkA7edx4MeX_E7sb-2CTcUtNWuTgT84M6mirMkde9AJB9A8f333x82sgahdVVQ6GxSYo4ugxXdTAOVsZHGfhrMkim8R18fh2Z5pXnueCe3D8uaXMySdejzdzr9HbJjoGLVmtu3z2yoZN9sjUwBfEDct1KkP5hhjJ4SSq1xAvE-mlm3U-w1S6x4GT4hngYFGi1WzVW49ZtYj2_ZrPpIRn1uk-dvm34EGzFfC-zlQLsEYGHjgFTqKbbZCqgMnIh5mFC-FS4EdfaYVqymDa0qyhTPpNUY2lMc0WPSCGZJvqEWDISfswloh_BfK2kikUcQXCmRMRkIEvkaqGSUJlh4chZ8R7mRWufh6sKLJHLpfTHfEjGGrkKaDdM9NtkzfvyQu-h2Upp-Gv4EjlfvoZNgJUNkejp11ymySC0A5njub2WP0J54DHKnNP_P35GtpFJPm_I9sqkkM2-dAXwRiar-aKCZ6PjVkmx3R0-PP4Al-_PjA |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LT9tAEB5BKlEuVQsUQqFdJDghg727XgdVVZXyUAIELoC4md31GoGIkyahiD_Fb2TGjwCH9MZ5R5Y1j51vdl4A6yjihjI6wLDEz59ulKcjtMeUi9BPaCmkT_3OnRPVOpeHl-HlFDxVvTBUVlndiflFnfQsvZFv8wiRfYPG9__u__VoaxRlV6sVGoVaHLnHBwzZhr_aeyjfDc4P9s92W165VcCzMuQjz1r04An6uRQ9s93BIN5GwiQBRg5S61DoIFHO-dIZmYqGC6yQNpRGOEowOWUFfncaPkiBpkmd6bvBq3FVJdwuX6zKQnvEGNu02d5yHqA7DN64wOludzgZ3eZe7uAzfCrhKWsW-vQFplw2BzOdMgE_Dz-bGa2bGBANNWUNmb7WNwgx2WmXSvsyhjfRP4y_UWDsT3NLbinWztjFzWjQW4Dzd-HUV6hlvcwtATOJDlNlCG1pGTprbKrTBINBqxNpIlOHzYolsS2Hk9OOjLs4T5KHKn7NwDpsjKn7xVCOCXSryN04c7fdCecrFd_j0nSH8Yui1WFtfIxGR5kUnbnefUGzIzGURJrFQl7jHxEq4lJIf_n_H_8BH1tnneP4uH1y9A1maYt9XgzOV6A2Gty7VcQ6I_M9VzAGV--t0c-avgmp |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED91Q5p4QXyNFVYwEnuasia242RCCJVuVcvYxwNDe8tsx0Gb1nS0HYh_jb-Ou8Qp46F727NPUXQfvt_5zv4BvEMTp8roCMuSsDq6UYFOMB4LLuIwJ1LIkO47Hx6p4an8fBafteBPcxeGxiqbPbHaqPOJpTPyLk8Q2af0fH-38GMRJ3uDj9c_AmKQok5rQ6dRu8iB-_0Ly7fZh9Ee2nqL88H-1_4w8AwDgZUxnwfWYjbPMecVmKXtLhb0NhEmj7CKkFrHQke5ci6UzshCpC6yQtpYGuGo2eSUFfjdFXiQiCSlGEv70a2nqzz09qdXfuge8UaXWO4t5xGmxui_dLgyHs-WI90q4w0ewyMPVVmv9q0n0HLlU1g79M34Z_C-VxL1xJRk6ILWjOnv-gLhJjse05hfyXBX-om1OBqPfertyB3FRiX7djGfTp7D6b1oah1Wy0npNoCZXMeFMoS8tIydNbbQRY6FodW5NIlpw3ajksz6h8qJL-MqqxrmscpuK7ANWwvp6_qBjiVyHdRuVrrL8ZL1zUbvmQ_jWfbP6drwdrGMAUhdFV26yU0tsyuxrESZF7W9Fj8iVMKlkOHLuz_-BtbQl7Mvo6ODV_CQCO2ruXC-Cavz6Y3rIOyZm9eVfzE4v2-H_gsWmw3f |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antiviral+Agents+against+Omicron+Subvariant+BA.4.6+In+Vitro&rft.jtitle=The+New+England+journal+of+medicine&rft.date=2023-02-02&rft.pub=Massachusetts+Medical+Society&rft.issn=0028-4793&rft.eissn=1533-4406&rft.volume=388&rft.issue=5&rft_id=info:doi/10.1056%2FNEJMc2216611&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-4793&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-4793&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-4793&client=summon |